Preferred Label : Vemurafenib;

MeSH definition : An indole sulfonamide compound and inhibitor of BRAF KINASES that is used for the treatment of unresectable or metastatic MELANOMA.;

MeSH hyponym : PLX 4032; RG-7204; RG 7204;

MeSH CAS label : 1-Propanesulfonamide, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2,3-b)pyridin-3-yl)carbonyl)-2,4-difluorophenyl)-;

UNII : 207SMY3FQT;

Details


Main resources

You can consult :

An indole sulfonamide compound and inhibitor of BRAF KINASES that is used for the treatment of unresectable or metastatic MELANOMA.

https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf
2020
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Vemurafenib
drug approval
europe
treatment outcome
vemurafenib
adult
melanoma
administration, oral
BRAF V600E Mutation Present
protein kinase inhibitors
protein kinase inhibitors
BRAF protein, human
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Vemurafenib
proto-oncogene proteins b-raf

---
https://www.has-sante.fr/jcms/p_3212633/fr/zelboraf
2020
false
false
false
France
vemurafenib
protein kinase inhibitors
treatment outcome
insurance, health, reimbursement
adult
administration, oral
melanoma
neoplasm metastasis
evaluation of the transparency committee
Vemurafenib

---
http://conseil-scientifique.public.lu/fr/publications/oncologie/vemurafenib-mise-a-jour-2018.html
2018
false
false
true
Luxembourg
French
administration, oral
vemurafenib
guidelines for drug use
BRAF protein, human
protein kinase inhibitors
melanoma
neoplasm metastasis
Metastatic Melanoma
BRAF V600E Mutation Present
Unresectable Malignant Neoplasm
adult
antineoplastic combined chemotherapy protocols
Off-Label use
mutation
melanoma
indoles
sulfonamides
proto-oncogene proteins b-raf
Vemurafenib

---
https://ansm.sante.fr/informations-de-securite/zelboraf-cotellic-v-rappel-du-risque-datteintes-opthalmiques-et-de-leur-prise-en-charge
2018
false
false
false
France
French
pharmacovigilance note
retinal diseases
vision disorders
cobimetinib
continuity of patient care
mass screening
risk
guidelines for drug use
pharmacovigilance
uveitis
cobimetinib
indoles
sulfonamides
azetidines
piperidines
Vemurafenib

---
http://www.has-sante.fr/portail/jcms/c_2755482/fr/zelboraf
2017
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
indoles
sulfonamides
Vemurafenib

---
http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2016-12-fra.php#zelb
2016
false
false
false
Canada
French
English
drug evaluation
risk assessment
vemurafenib
vemurafenib
melanoma
neoplasm metastasis
protein kinase inhibitors
anemia, aplastic
bone marrow
aplastic anemia secondary to chemicals
product surveillance, postmarketing
indoles
sulfonamides
Vemurafenib

---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-BRAF-en-monotherapie-vemurafenib-dabrafenib-Medicaments-ciblant-BRAF-ou-MEK-en-association-vemurafenib-cobimetinib-dabrafenib-trametinib
2016
false
false
false
France
French
guidelines for drug use
practice guideline
patients guideline
protein kinase inhibitors
protein kinase inhibitors
Drug-Related side effects and adverse reactions
administration, oral
drug interactions
vemurafenib
vemurafenib
antineoplastic combined chemotherapy protocols
vemurafenib
dabrafenib
dabrafenib
dabrafenib
BRAF protein, human
Metastatic Melanoma
melanoma
melanoma
neoplasm metastasis
BRAF Gene Mutation
continuity of patient care
drug monitoring
interdisciplinary communication
protein kinase inhibitors
vemurafenib
dabrafenib
pregnancy
imidazoles
oximes
imidazoles
oximes
proto-oncogene proteins b-raf
imidazoles
oximes
indoles
sulfonamides
indoles
sulfonamides
indoles
sulfonamides
Vemurafenib
Vemurafenib
Vemurafenib

---
Skin-cancer drug Zelboraf (vemurafenib): new warning on the risk of pancreatitis
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/43697a-fra.php
2015
false
false
false
Canada
French
English
pancreatitis
pharmacovigilance note
vemurafenib
vemurafenib
melanoma
protein kinase inhibitors
vemurafenib
adult
protein kinase inhibitors
Drug-induced acute pancreatitis (disorder)
indoles
sulfonamides
indoles
sulfonamides
Vemurafenib
Vemurafenib

---
ZELBORAF (vemurafenib) - Risk of Radiation Sensitization or Radiation Recall Reaction
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2015/56368a-fra.php
2015
false
false
false
Canada
French
English
pharmacovigilance note
radiation injuries
melanoma
melanoma
vemurafenib
vemurafenib
radiotherapy
adult
BRAF V600E Mutation Present
chemoradiotherapy
indoles
sulfonamides
Vemurafenib

---
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/38867a-fra.php
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/38869a-fra.php
2014
false
Canada
French
English
vemurafenib
vemurafenib
Chemical and Drug Induced Liver Injury
continuity of patient care
pharmacovigilance note
Chemical and Drug Induced Liver Injury
melanoma
indoles
sulfonamides
Vemurafenib

---
http://www.prescrire.org/Fr/3/31/49741/0/2014/ArchiveNewsDetails.aspx?page=1
2014
false
false
false
France
French
french abstract
neoplasm metastasis
melanoma
vemurafenib
vemurafenib
indoles
sulfonamides
Vemurafenib

---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/904
2013
false
France
French
Stage IV Cutaneous Melanoma AJCC v6 and v7
melanoma, cutaneous malignant
melanoma
neoplasm metastasis
skin neoplasms
journal article
antineoplastic agents
antineoplastic agents
antibodies, monoclonal
indoles
sulfonamides
melanoma
Vemurafenib
Vemurafenib

---
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/35165a-fra.php
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/35171a-fra.php
2013
false
Canada
English
French
drug hypersensitivity syndrome
vemurafenib
vemurafenib
neoplasms
disease progression
canada
eosinophilia
protein kinase inhibitors
pharmacovigilance note
genes, ras
patient education handout
indoles
sulfonamides
Vemurafenib

---
https://www.ema.europa.eu/medicines/human/EPAR/Zelboraf
2012
false
United Kingdom
French
English
syndication feed
indoles
indoles
sulfonamides
sulfonamides
administration, oral
protein kinase inhibitors
protein kinase inhibitors
vemurafenib
melanoma
BRAF protein, human
proto-oncogene proteins b-raf
vemurafenib
vemurafenib
drug approval
adult
treatment outcome
melanoma
neoplasm metastasis
drug interactions
pregnancy
breast feeding
proto-oncogene proteins b-raf
mutation
clinical trials, phase iii as topic
survival analysis
clinical trials, phase ii as topic
drug evaluation, preclinical
drug evaluation
summary of product characteristics
package leaflet
Vemurafenib
Vemurafenib

---
http://www.has-sante.fr/portail/jcms/c_1329823/zelboraf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-10/zelboraf_03102012_avis_ct12121.pdf
2012
false
France
French
administration, oral
insurance, health, reimbursement
evaluation of the transparency committee
vemurafenib
vemurafenib
vemurafenib
protein kinase inhibitors
protein kinase inhibitors
adult
neoplasm metastasis
melanoma
indoles
indoles
sulfonamides
sulfonamides
Vemurafenib
Vemurafenib

---
http://www.has-sante.fr/portail/jcms/c_1355322/zelboraf-vemurafenib-inhibiteur-de-la-proteine-kinase-braf
http://www.has-sante.fr/portail/jcms/c_1355321/zelboraf-synthese-ct12121
2012
France
French
melanoma
evaluation of the transparency committee
guidelines for drug use
vemurafenib
indoles
sulfonamides
proto-oncogene proteins b-raf
Vemurafenib

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00164
2012
false
false
false
Canada
vemurafenib
Product containing vemurafenib (medicinal product)
drug information
indoles
sulfonamides
Vemurafenib

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.